• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

Market Overview:

The global migraine drugs market grew at a CAGR of around 14% during 2014-2019. Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient’s medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.

A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. Besides this, the testing of migraine drugs for the treatment of the coronavirus disease (COVID-19) is expected to create a positive influence on the market growth. For instance, Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, which was examining Zavegepant for the treatment of acute migraines, has commenced the clinical trial on the same drug to mitigate the neuro-immune consequences among COVID-19 patients. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth. Looking forward, IMARC Group expects the global migraine drugs market to exhibit strong growth during the forecast period (2020-2025).

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global migraine drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region,  treatment type, drug type, route of administration and distribution channel.

Breakup by Treatment Type:

  • Abortive Treatment
  • Preventive Treatment 
     

Breakup by Drug Type:

  • Triptans
  • Ergot Alkaloids
  • NSAIDs
  • Acetylcholine Inhibitors/ Neurotoxins
  • Ditans
  • CGRP mAbs
  • Others
     

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others
     

Breakup by Distribution Channel:

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:

  • How has the global migraine drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global migraine drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global migraine drugs market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology 

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Migraine Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Treatment Type
    6.1    Abortive Treatment
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Preventive Treatment
        6.2.1 Market Trends
        6.2.2 Market Forecast
7    Market Breakup by Drug Type
    7.1    Triptans
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Ergot Alkaloids
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    NSAIDs
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Acetylcholine Inhibitors/ Neurotoxins
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    Ditans
        7.5.1 Market Trends
        7.5.2 Market Forecast
    7.6    CGRP mAbs
        7.6.1 Market Trends
        7.6.2 Market Forecast
    7.7    Others
        7.7.1 Market Trends
        7.7.2 Market Forecast
8    Market Breakup by Route of Administration
    8.1    Oral
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Injectable
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Others
        8.3.1 Market Trends
        8.3.2 Market Forecast
9    Market Breakup by Distribution Channel
    9.1    Hospital-Based Pharmacies
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Retail Pharmacies
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Others
        9.3.1 Market Trends
        9.3.2 Market Forecast
10    Market Breakup by Region
    10.1    North America
        10.1.1 United States
           10.1.1.1 Market Trends
           10.1.1.2 Market Forecast
        10.1.2 Canada
           10.1.2.1 Market Trends
           10.1.2.2 Market Forecast
    10.2    Asia Pacific
        10.2.1 China
           10.2.1.1 Market Trends
           10.2.1.2 Market Forecast
        10.2.2 Japan
           10.2.2.1 Market Trends
           10.2.2.2 Market Forecast
        10.2.3 India
           10.2.3.1 Market Trends
           10.2.3.2 Market Forecast
        10.2.4 South Korea
           10.2.4.1 Market Trends
           10.2.4.2 Market Forecast
        10.2.5 Australia
           10.2.5.1 Market Trends
           10.2.5.2 Market Forecast
        10.2.6 Indonesia
           10.2.6.1 Market Trends
           10.2.6.2 Market Forecast
        10.2.7 Others
           10.2.7.1 Market Trends
           10.2.7.2 Market Forecast
    10.3    Europe
        10.3.1 Germany
           10.3.1.1 Market Trends
           10.3.1.2 Market Forecast
        10.3.2 France
           10.3.2.1 Market Trends
           10.3.2.2 Market Forecast
        10.3.3 United Kingdom
           10.3.3.1 Market Trends
           10.3.3.2 Market Forecast
        10.3.4 Italy
           10.3.4.1 Market Trends
           10.3.4.2 Market Forecast
        10.3.5 Spain
           10.3.5.1 Market Trends
           10.3.5.2 Market Forecast
        10.3.6 Russia
           10.3.6.1 Market Trends
           10.3.6.2 Market Forecast
        10.3.7 Others
           10.3.7.1 Market Trends
           10.3.7.2 Market Forecast
    10.4    Latin America
        10.4.1 Brazil
           10.4.1.1 Market Trends
           10.4.1.2 Market Forecast
        10.4.2 Mexico
           10.4.2.1 Market Trends
           10.4.2.2 Market Forecast
        10.4.3 Others
           10.4.3.1 Market Trends
           10.4.3.2 Market Forecast
    10.5    Middle East and Africa
        10.5.1 Market Trends
        10.5.2 Market Breakup by Country
        10.5.3 Market Forecast
11    SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12    Value Chain Analysis
13    Porters Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14    Price Analysis
15    Competitive Landscape

    15.1    Market Structure
    15.2    Key Players
    15.3    Profiles of Key Players
        15.3.1    Abbott Laboratories
           15.3.1.1 Company Overview
           15.3.1.2 Product Portfolio 
           15.3.1.3 Financials
           15.3.1.4 SWOT Analysis
        15.3.2    Allergan Plc (Abbvie Inc.)
           15.3.2.1 Company Overview
           15.3.2.2 Product Portfolio 
           15.3.2.3 SWOT Analysis
        15.3.3    Amgen Inc.
           15.3.3.1 Company Overview
           15.3.3.2 Product Portfolio 
           15.3.3.3 SWOT Analysis
        15.3.4    AstraZeneca Plc
           15.3.4.1 Company Overview
           15.3.4.2 Product Portfolio 
           15.3.4.3 Financials
           15.3.4.4 SWOT Analysis
        15.3.5    Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
           15.3.5.1 Company Overview
           15.3.5.2 Product Portfolio 
           15.3.5.3 Financials
           15.3.5.4 SWOT Analysis
        15.3.6    Eisai Co. Ltd.
           15.3.6.1 Company Overview
           15.3.6.2 Product Portfolio 
           15.3.6.3 Financials
           15.3.6.4 SWOT Analysis
        15.3.7    Eli Lilly and Company
           15.3.7.1 Company Overview
           15.3.7.2 Product Portfolio 
           15.3.7.3 Financials
           15.3.7.4 SWOT Analysis
        15.3.8    Endo International Plc
           15.3.8.1 Company Overview
           15.3.8.2 Product Portfolio 
           15.3.8.3 Financials
           15.3.8.4 SWOT Analysis
        15.3.9    GlaxoSmithKline Plc
           15.3.9.1 Company Overview
           15.3.9.2 Product Portfolio 
           15.3.9.3 Financials
           15.3.9.4 SWOT Analysis
        15.3.10    Johnson & Johnson
           15.3.10.1 Company Overview
           15.3.10.2 Product Portfolio 
           15.3.10.3 Financials
           15.3.10.4 SWOT Analysis
        15.3.11    Merck & Co.
           15.3.11.1 Company Overview
           15.3.11.2 Product Portfolio 
           15.3.11.3 Financials
           15.3.11.4 SWOT Analysis
        15.3.12    Novartis AG
           15.3.12.1 Company Overview
           15.3.12.2 Product Portfolio 
           15.3.12.3 Financials
           15.3.12.4 SWOT Analysis
        15.3.13    Pfizer Inc.
           15.3.13.1 Company Overview
           15.3.13.2 Product Portfolio 
           15.3.13.3 Financials
           15.3.13.4 SWOT Analysis
        15.3.14    Sanofi SA
           15.3.14.1 Company Overview
           15.3.14.2 Product Portfolio 
           15.3.14.3 Financials
           15.3.14.4 SWOT Analysis
        15.3.15    Teva Pharmaceutical Industries Limited
           15.3.15.1 Company Overview
           15.3.15.2 Product Portfolio 
           15.3.15.3 Financials
           15.3.15.4 SWOT Analysis

List of Figures

Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2014-2019
Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2019
Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2019
Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2019
Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2019
Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2019
Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2020-2025
Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2014 & 2019
Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2014 & 2019
Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2014 & 2019
Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2014 & 2019
Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2014 & 2019
Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2014 & 2019
Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2014 & 2019
Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2014 & 2019
Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2014 & 2019
Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2014 & 2019
Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2014 & 2019
Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2014 & 2019
Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2014 & 2019
Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
Figure 89: Global: Migraine Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2019 and 2025
Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2020-2025
Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2020-2025
Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2020-2025
Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2020-2025
Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2020-2025
Table 7: Global: Migraine Drugs Market Structure
Table 8: Global: Migraine Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com

Social Links